- Comment: Post COVID-19 Vaccination Encephalitis as a Cause of Subacute Progressive Dementia: A Case Report and Literature Review
-
Kleebayoon A, Wiwanitkit V
- KMID: 2545095
- Dement Neurocogn Disord.
- 2023 Jul;22(3):112-113.
- doi: 10.12779/dnd.2023.22.3.112
-
- CITED
-
- Close
- SHARE
-
- Close
- Dot-Like Hippocampal Hyperintensities on DiffusionWeighted MRI in a Patient With Vomiting Caused by Benign Paroxysmal Positional Vertigo Without Amnesia
-
Shin DS, Choi EJ
- KMID: 2545096
- Dement Neurocogn Disord.
- 2023 Jul;22(3):114-116.
- doi: 10.12779/dnd.2023.22.3.114
-
- CITED
-
- Close
- SHARE
-
- Close
- Comparing Neurofilament Light Chain Levels in Serum and Plasma
-
Kwon HS, Lee H, Kim YS, Choi H, Lee KY, Lee YJ, Lee EH, Hwang M, Park H, Koh SH
- KMID: 2545094
- Dement Neurocogn Disord.
- 2023 Jul;22(3):109-111.
- doi: 10.12779/dnd.2023.22.3.109
-
- CITED
-
- Close
- SHARE
-
- Close
- A Patient With Fahr’s Disease Who Presented Prominent Visuospatial Dysfunction
-
Lee D, Chae SY, Kim SH, Kim HJ
- KMID: 2545097
- Dement Neurocogn Disord.
- 2023 Jul;22(3):117-119.
- doi: 10.12779/dnd.2023.22.3.117
-
- CITED
-
- Close
- SHARE
-
- Close
- Association of Type 2 Diabetes Mellitus With Perivascular Spaces and Cerebral Amyloid Angiopathy in Alzheimer’s Disease: Insights From MRI Imaging
-
Munis
- KMID: 2545098
- Dement Neurocogn Disord.
- 2023 Jul;22(3):87-99.
- doi: 10.12779/dnd.2023.22.3.87
Background and Purpose: According to the amyloid cascade hypothesis, fibrillary amyloid-beta load in the brain causes Alzheimer’s disease (AD) with toxic effects. Recently, perivascular spaces (PVSs), fluid-filled cavities around small... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of GV1001 on Language Dysfunction in Patients With Moderate-to-Severe Alzheimer’s Disease: Post Hoc Analysis of Severe Impairment Battery Subscales
-
Kwon HS, Koh SH, Choi SH, Jeong JH, Na HR, Lee CN, Yang Y, Lee AY, Lee JH, Park KW, Han HJ, Kim BC, Park J, Lee JY, Lee KY, Kim S
- KMID: 2545093
- Dement Neurocogn Disord.
- 2023 Jul;22(3):100-108.
- doi: 10.12779/dnd.2023.22.3.100
Background and Purpose: The efficacy and safety of GV1001 have been demonstrated in patients with moderate-to-severe Alzheimer’s disease (AD). In this study, we aimed to further demonstrate the effectiveness of... -
- CITED
-
- Close
- SHARE
-
- Close
